Claims for Patent: 9,907,788

Summary for Patent: 9,907,788

Title:	Inhibition of crystal growth of roflumilast
Abstract:	Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glycol in the composition. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment.
Inventor(s):	Osborne; David W. (Fort Collins, CO)
Assignee:	Arcutis Inc. (Menlo Park, CA)
Application Number:	15/676,373
Patent Claims:	1. A method of inhibiting phosphodiesterase 4 in a patient, comprising administering a composition comprising roflumilast and hexylene glycol to a patient in need thereof. 2. The method according to claim 1 wherein said patient is suffering from an inflammatory condition. 3. The method according to claim 2, wherein said patient is suffering from atopic dermatitis. 4. The method according to claim 1, wherein said composition comprises suspended roflumilast particles. 5. The method according to claim 1, wherein said hexylene glycol is added in an amount of 0.1-20% w/w. 6. The method according to claim 5, wherein said hexylene glycol is added in an amount of 0.25-8% w/w. 7. The method according to claim 6, wherein said hexylene glycol is added in an amount of 0.5-2% w/w. 8. The method according to claim 1, wherein said roflumilast composition comprises 0.005-2% roflumilast. 9. The method according to claim 1, wherein said roflumilast composition is selected from the group consisting of an oil in water emulsion, a thickened aqueous gel, a thickened hydroalcoholic gel, a hydrophilic gel, and a hydrophilic or hydrophobic ointment. 10. The method according to claim 1, wherein said roflumilast composition further comprises at least one additional component selected from the group consisting of a solvent, moisturizer, surfactant or emulsifier, polymer or thickener, antifoaming agent, preservative, antioxidant, sequestering agent, stabilizer, buffer, pH adjusting solution, skin penetration enhancer, film former, dye, pigment, and fragrance. 11. The method according to claim 1, wherein said roflumilast composition further comprises an additional active agent selected from the group consisting of anthralin, azathioprine, tacrolimus, coal tar, methotrexate, methoxsalen, salicylic acid, ammonium lactate, urea, hydroxyurea, 5-fluorouracil, propylthouracil, 6-thioguanine, sulfasalazine, mycophenolate mofetil, fumaric acid esters, corticosteroids, corticotropin, vitamin D analogues, acitretin, tazarotene, cyclosporine, resorcinol, colchicine, adalimumab, ustekinumab, infliximab, bronchodialators, and antibiotics. 12. The method according to claim 1, wherein said composition is administered by topical, parenteral or pulmonary administration. 13. The method according to claim 1, wherein said composition is administered by topical administration. 14. The method according to claim 1, further comprising adding diethylene glycol monoethyl ether to said composition. 15. The method according to claim 1, wherein said composition comprises roflumilast, white petrolatum, isopropyl palmitate, cetearyl alcohol, dicetyl phosphate, ceteth-10 phosphate, hexylene glycol, diethylene glycol monoethyl ether, methylparaben, propylparaben, and purified water. 16. The method according to claim 15, wherein the composition comprises: TABLE-US-00003 roflumilast 0.5% w/w white petrolatum 10.0% w/w isopropyl palmitate 5.0% w/w cetearyl alcohol, dicetyl phosphate, 10.0% w/w and ceteth-10 phosphate hexylene glycol 2.0% w/w diethylene glycol monoethyl ether 25.0% w/w methylparaben 0.2% w/w propylparaben 0.05% w/w, and purified water q.s. ad 100 (47.25%). 17. The method according to claim 1, wherein said composition is administered 1-2 times per day.